Literature DB >> 7793651

Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics.

E D Kharasch1, M D Karol, C Lanni, R Sawchuk.   

Abstract

BACKGROUND: Sevoflurane has low blood and tissue solubility and is metabolized to free fluoride and hexafluoroisopropanol (HFIP). Although sevoflurane uptake and distribution and fluoride formation have been described, the pharmacokinetics of HFIP formation and elimination are incompletely understood. This investigation comprehensively characterized the simultaneous disposition of sevoflurane, fluoride, and HFIP.
METHODS: Ten patients within 30% of ideal body weight who provided institutional review board-approved informed consent received sevoflurane (2.7% end-tidal, 1.3 MAC) in oxygen for 3 h after propofol induction, after which anesthesia was maintained with propofol, fentanyl, and nitrous oxide. Sevoflurane and unconjugated and total HFIP concentrations in blood were determined during anesthesia and for 8 h thereafter. Plasma and urine fluoride and total HFIP concentrations were measured during and through 96 h after anesthetic administration. Fluoride and HFIP were quantitated using an ion-selective electrode and by gas chromatography, respectively.
RESULTS: The total sevoflurane dose, calculated from the pulmonary uptake rate, was 88.8 +/- 9.1 mmol. Sevoflurane was rapidly metabolized to the primary metabolites fluoride and HFIP, which were eliminated in urine. HFIP circulated in blood primarily as a glucuronide conjugate, with unconjugated HFIP < or = 15% of total HFIP concentrations. In blood, peak unconjugated HFIP concentrations were less than 1% of peak sevoflurane concentrations. Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively. Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol. Compared with the estimated sevoflurane uptake, 4.9 +/- 0.5% of the dose taken up was eliminated in the urine as HFIP. For fluoride, 3.7 +/- 0.4% of the sevoflurane dose taken up was eliminated in the urine, which, because a portion of fluoride is sequestered in bone, corresponded to approximately 5.6% of the sevoflurane dose metabolized to fluoride.
CONCLUSIONS: Sevoflurane was rapidly metabolized to fluoride and HFIP, which was rapidly glucuronidated and eliminated in the urine. The overall extent of sevoflurane metabolism was approximately 5%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793651     DOI: 10.1097/00000542-199506000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  19 in total

1.  Cytokine profile in patients undergoing minimally invasive surgery with balanced anesthesia.

Authors:  José Eduardo B Orosz; Mariana G Braz; Márjorie A Golim; Márcio Antônio A Barreira; Denise Fecchio; Leandro G Braz; José Reinaldo C Braz
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

2.  Insight into the beneficial immunomodulatory mechanism of the sevoflurane metabolite hexafluoro-2-propanol in a rat model of endotoxaemia.

Authors:  M Urner; M Schläpfer; I K Herrmann; M Hasler; R R Schimmer; C Booy; B Roth Z'graggen; H Rehrauer; F Aigner; R D Minshall; W J Stark; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2015-07-07       Impact factor: 4.330

3.  Urinary sevoflurane and hexafluoro-isopropanol as biomarkers of low-level occupational exposure to sevoflurane.

Authors:  Antonio Accorsi; Barbara Morrone; Irene Domenichini; Simona Valenti; Giovanni Battista Raffi; Francesco Saverio Violante
Journal:  Int Arch Occup Environ Health       Date:  2005-04-30       Impact factor: 3.015

4.  The effect of sevoflurane on developing A/J strain mouse embryos using a whole-embryo culture system--the incidence of cleft lip in culture embryos.

Authors:  Morimasa Yamada; Naoki Yamamoto; Saori Ohgami; Mayuko Kanazawa; Jun Harada; Norikazu Ohno; Nagato Natsume
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-11-21       Impact factor: 2.416

5.  The volatile anesthetic sevoflurane reduces neutrophil apoptosis via Fas death domain-Fas-associated death domain interaction.

Authors:  Sophia Koutsogiannaki; Lifei Hou; Hasan Babazada; Toshiaki Okuno; Nathan Blazon-Brown; Sulpicio G Soriano; Takehiko Yokomizo; Koichi Yuki
Journal:  FASEB J       Date:  2019-08-30       Impact factor: 5.191

Review 6.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 7.  Induction of anaesthesia: a guide to drug choice.

Authors:  Nathalie Nathan; Isabelle Odin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Comparative tolerability profiles of the inhaled anaesthetics.

Authors:  J P Fee; G H Thompson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

9.  Effects of A-line Autoregression Index (AAI) monitoring on recovery after sevoflurane anesthesia for bariatric surgery.

Authors:  Ulderico Freo; Michele Carron; Federico Innocente; Mirto Foletto; Donato Nitti; Carlo Ori
Journal:  Obes Surg       Date:  2011-07       Impact factor: 4.129

Review 10.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.